A Comparison of NSAIDs for Acute, Non-radicular Low Back Pain. A Randomized Trial
Phase: PHASE4
Conditions: Back Pain Without Radiation, Low Back Pain
Sponsor: Montefiore Medical Center

ketorolac vs other NSAIDS randomized trial Version 03312019
1
A comparison of NSAIDs for acute, non-radicular low back pain. A randomized trial
IRB NUMBER: 2019-10026
IRB APPROVAL DATE: 04/17/2019

ketorolac vs other NSAIDS randomized trial Version 03312019
2
Specific Aims
More than 2.5 million patients present to US emergency departments (ED) annually with low back 
pain.(1) Up to ½ of ED patients with acute, new onset low back pain (LBP) report persistent moderate 
or severe pain one week after the ED visit.(2-5) Non-steroidal anti-inflammatory drugs (NSAIDs) are 
an effective treatment of acute LBP, though their impact is only modest.(6) Combining NSAIDS with 
oxycodone,(3) skeletal muscle relaxants,(2, 3) or diazepam(5) does not improve outcomes. 
Ketorolac is an NSAID that can be used for the management of moderately severe acute pain that 
requires analgesia at the opioid level; its mechanism of action, similar to other NSAIDs, is not 
completely understood. (7) There is some literature suggesting that ketorolac may afford faster 
and superior pain relief when compared to other NSAIDS.(8,9)
Given the poor pain and functional outcomes that persist beyond an ED visit for acute LBP, we 
propose a clinical trial to determine whether there is a difference in efficacy between the NSAIDs 
ketorolac, ibuprofen, and diclofenac and for the treatment of acute, non-traumatic, non-radicular low 
back pain. We will test the following hypothesis:
A daily regimen of ketorolac will provide greater relief of LBP than ibuprofen or diclofenac 5 days 
after an ED visit, as measured by the Roland Morris Disability Questionnaire.
IRB NUMBER: 2019-10026
IRB APPROVAL DATE: 04/17/2019

ketorolac vs other NSAIDS randomized trial Version 03312019
3
Overview.
This will be a three armed, double-blind, comparative effectiveness study, in which we enroll patients 
during an ED visit for musculoskeletal LBP and follow them by telephone two and five days later. 
Patients will be randomized to receive a 5 day supply of ketorolac, diclofenac, or ibuprofen. Every 
patient will receive a low back pain education session. 
Subject selection. 
Our goal is to include in this study a broad representation of patients with musculoskeletal back pain 
who are likely to respond to the investigational medications and who would not be considered 
candidates for spinal surgery or targeted epidural intervention. We hope for a widely generalizable 
study and therefore will not require diagnoses to be contingent on advanced imaging studies. 
Inclusion criteria:
-Present to ED primary for management of LBP, defined as pain originating between the lower border 
of the scapulae and the upper gluteal folds. Flank pain, that is pain originating from tissues lateral to 
the paraspinal muscles, will not be included.
- Musculoskeletal etiology of low back. Patients with non-musculoskeletal etiologies such as urinary 
tract infection, ovarian cysts, or influenza like illness will be excluded. The primary clinical diagnosis, 
at the conclusion of the ED visit, must be a diagnosis consistent with non-traumatic, non-radicular, 
musculoskeletal LBP.
-Patient is to be discharged home. 
- Age 18-64 Enrollment will be limited to adults younger than 65 years because of the increased risk of 
adverse medication effects in the elderly.
-Non-radicular pain. Patients will be excluded if the pain radiates below the gluteal folds in a radicular 
pattern. 
-Pain duration <2 weeks (336 hours). Patients with more than two weeks of pain are at increased risk 
of poor pain and functional outcomes.(10)
-Prior to the acute attack of LBP, back pain cannot occur more frequently than once per month. 
Patients with more frequent back pain are at increased risk of poor pain and functional outcomes.(10) 
-Non-traumatic LBP: no substantial and direct trauma to the back within the previous month
-Functionally impairing back pain: A baseline score of > 5 on the Roland-Morris Disability 
Questionnaire (Appendix)
Exclusion criteria:
-Not available for follow-up
-Pregnant 
-Chronic pain syndrome defined as use of any analgesic medication on a daily or near-daily basis
-Allergic to or intolerant of investigational medications
-Contra-indications to investigational medications: 1) known peptic ulcer disease, chronic dyspepsia, 
or history of gastrointestinal bleed 2) Severe heart failure (NYHA 2 or worse) 3) Chronic kidney 
disease (GFR <60ml/min) 4) Current use of anti-coagulants 5) cirrhosis (Child Pugh A or worse) or 
hepatitis (transaminases 2x the upper limit of normal)
IRB NUMBER: 2019-10026
IRB APPROVAL DATE: 04/17/2019

ketorolac vs other NSAIDS randomized trial Version 03312019
4
Investigational medication.
A. Ibuprofen 600mg, orally, every 8 hours as needed
B. Diclofenac 50 mg, orally, every 8 hours as needed
C. Ketorolac 10 mg, orally, every 8 hours as needed
In an effort to maximize effectiveness while minimizing side effects, patients will be instructed to 
take one capsule of the investigational medication every 8 hours as needed for low back pain. All 
study patients will be given a five day supply of investigational medication. 
Outcome measures.
1. Roland Morris LBP Disability Questionnaire (RMDQ)--Reproduced in the Appendix. This 24-item 
LBP functional scale is recommended for use in LBP research.(11) Its yes/ no format is amenable to 
telephone follow-up. We have used it successfully to obtain post-ED follow-up in five previous LBP 
studies involving more than 1500 patients.
2. Ordinal pain scale (“severe”, “moderate”, “mild”, or “none”). Study participants will be asked to 
describe their worst back pain in the previous 24 hours.
3. Medication requirements: “What medications did you use to treat your low back pain in the previous 
24 hours?” 
4. Low back pain frequency: “Over the last 24 hours, how often were you in pain?  Not at all, Rarely, 
Sometimes, Usually, Always”.  Low back pain symptomatology is quite variable. Some patients may 
experience no pain unless they move a certain way. Others may experience a constant low level of 
pain. This question will help determine the burdensomeness of the LBP in the patient’s daily life.
5. Satisfaction, as measured by response to this question: The next time you go to the ER with low 
back pain, do you want to get the same combination of medications?
Primary outcome
The change in Roland Morris Disability scale between the baseline ED visit and the five day follow-up 
(Roland-Morris baseline - Roland-Morris day 5). The baseline questions will refer to the time period 
immediately prior to ED presentation (Before you came to the ER today, were you able to…..).
Secondary outcomes
   The following outcomes will be assessed 48 hours and 5 days after ED discharge:
1. Worst LBP over the previous 24 hours, using a four point ordinal scale: severe, moderate, mild, 
or none
2. Frequency of low back pain using the five point Likert scale: Not at all, Rarely, Sometimes, 
Usually, Always
3. Use of any analgesic or LBP medication within the previous 24 hours.
4. Absolute RMDQ score
5. Day post ED discharge able to return to all usual activities
6. Number of visits to any healthcare provider.
7. Satisfaction with treatment 
8. Frequency of adverse events including 
-GI side effects (dyspepsia, nausea, and bleeding)
-All other side effects
IRB NUMBER: 2019-10026
IRB APPROVAL DATE: 04/17/2019

ketorolac vs other NSAIDS randomized trial Version 03312019
5
Randomization and blinding
The pharmacist will perform randomization in blocks of 4 based on a sequence generated at 
http://randomization.com The investigational medication will be masked by placing tablets into 
identical capsules, which will be packed with scant amounts of lactose and sealed. This masking will 
take place in a secure location inaccessible to ED personnel. All clinical staff and patients will be 
blinded. Patients will be presented with one bottle of investigational medication labeled with dosing 
instructions.  
Details of protocol
Prior to discharge from the ED and after the patient’s pain has been controlled, the healthcare provider 
will refer appropriate patients to study personnel for screening. Research associates will ascertain 
baseline socio-demographic information, low back pain history, and baseline variables discussed 
above. A urine pregnancy test will be performed. Research personnel will provide each patient with a 
15-minute educational intervention. This will be based on NIAMS’s Handout on Health: Back Pain 
information webpage (available at http://www.niams.nih.gov/Health_Info/Back_Pain/default.asp) 
Research personnel will review each section of the information sheet with the patient and elicit 
questions. Patients will be discharged with one medication vial, containing a five day supply of 
ketorolac, diclofenac or ibuprofen. Patients will be cautioned not to take off protocol LBP medication 
without first consulting with a healthcare provider. Patients will be cautioned not to drink alcohol 
while using study medications. Patients will be encouraged to follow-up with their primary care 
physician. Research personnel will use REDCap form to capture data. Follow-up phone calls will be 
conducted 48 hours, and five days after ED discharge. Follow-up will be attempted daily until 
successful. For patients difficult to contact, express courier or home visit will be used to obtain follow-
up information.
Analysis
An intention-to-treat analysis will be performed among all patients for whom primary outcome data is 
available. The primary outcome will be a comparison of the change in RMDQ between baseline and 
day 5. We will look for differences between groups using ANOVA. The mean difference between 
groups will be reported with 95%CI—if this 95%CI does not cross zero, the result will be considered 
statistically significant. For patients with missing 5 day follow-up data, we will perform two sensitivity 
analyses in which we assume universally good outcomes among all patients with missing data in one 
arm and universally bad arms among those with missing data in the other; we will the reverse these 
assumptions. Secondary outcomes will be reported as rates with 95%CI. The between group difference 
will be reported with 95%CI. A per protocol efficacy analysis will be conducted among those patients 
who use the investigational medication at least once.
Sample size calculation
We based assumptions on a recently completed RCT of LBP treatment.(3) The mean improvement in 
RMDQ among those who receive an NSAID alone was 10.2. The standard deviation was 8.9. A widely 
accepted minimum clinically important improvement of 5 points on the RMDQ would require those 
randomized to active medication to demonstrate a mean improvement of 15.2 on the RMDQ. Using a 
standard alpha of 0.05 and a beta of 0.20, we determined the need for 60 subjects in each arm. To 
account for protocol violations and patients lost-to-follow-up (typical lost-to-follow-up rate is 5-10%) 
and to ensure sufficient power for the per protocol analysis (in our previous ED-based LBP studies, up 
to 1/3 of enrolled patients have not used the medication more than once), we intend to enroll 66 
patients in each arm (total n= 198).
Data Safety Monitoring Committee
IRB NUMBER: 2019-10026
IRB APPROVAL DATE: 04/17/2019

ketorolac vs other NSAIDS randomized trial Version 03312019
6
 This committee will be comprised of Dr. Polly Bijur, PhD, an epidemiologist and Dr. David Esses, 
MD, the director of the Moses ED. The committee will meet every month with the PI to 1) monitor 
adverse events and develop strategies to minimize these; and, 2) monitor recruitment and enrollment. 
There will not be an interim analysis.
Consent
Study personnel will obtain informed consent once the patient’s pain has been controlled and the 
patient is ready for discharge from the ED. The attending physician will assess the patient’s capacity to 
consent to participate in this study. 
Risks/Benefits
NSAIDs are commonly used in more than 2.5 million annual US ED visits for LBP. Regardless of 
results, this study will have a national impact. All study subjects receive an NSAID and thus are likely 
to benefit. There may be a NSAID that is superior to the others in achieving pain relief. In addition to 
breach of confidentiality, which is unlikely, and inconvenience to the subject, which will undoubtedly 
occur, some subjects will possibly experience adverse medication effects. For the most part, these are 
minor events. Non-steroidals can cause life-threating gastro-intestinal bleeding, but this is unlikely in 
patients screened for gastro-intestinal illness who will take the medication for one week only. Non-
steroidals increase cardiovascular and and risk of renal injury and may worsen blood pressure 
control.
Data Storage & Confidentiality
Data will be stored and maintained in REDCap. Data analysis will occur on password-protected 
computers. Consent documents will be maintained in locked research cabinets. Only study personnel 
will have access to the data and consent documents.
IRB NUMBER: 2019-10026
IRB APPROVAL DATE: 04/17/2019

ketorolac vs other NSAIDS randomized trial Version 03312019
7
References
1.
Friedman BW, Chilstrom M, Bijur PE, Gallagher EJ. Diagnostic testing and treatment of low 
back pain in United States emergency departments: a national perspective. Spine. 
2010;35(24):E1406-11.
2.
Friedman BW, Cisewski D, Irizarry E, Davitt M, Solorzano C, Nassery A, et al. A 
Randomized, Double-Blind, Placebo-Controlled Trial of Naproxen With or Without 
Orphenadrine or Methocarbamol for Acute Low Back Pain. Ann Emerg Med. 2017.
3.
Friedman BW, Dym AA, Davitt M, Holden L, Solorzano C, Esses D, et al. Naproxen With 
Cyclobenzaprine, Oxycodone/Acetaminophen, or Placebo for Treating Acute Low Back 
Pain: A Randomized Clinical Trial. JAMA. 2015;314(15):1572-80.
4.
Friedman BW, Holden L, Esses D, Bijur PE, Choi HK, Solorzano C, et al. Parenteral 
corticosteroids for Emergency Department patients with non-radicular low back pain. 
The Journal of emergency medicine. 2006;31(4):365-70.
5.
Friedman BW, Irizarry E, C. S, Khankel N, Zapata J, Zias E, et al. Diazepam is no better than 
placebo when added to naproxen for acute low back pain. Annals of emergency medicine. 
2017.
6.
Chou R, Qaseem A, Snow V, Casey D, Cross JT, Jr., Shekelle P, et al. Diagnosis and treatment 
of low back pain: a joint clinical practice guideline from the American College of 
Physicians and the American Pain Society. Ann Intern Med. 2007;147(7):478-91.
7.
Roche Pharmaceuticals.  Toradol (Pharmaceutical insert). Retrieved on December 13, 
2018 from 
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/019645s019lbl.pdf. 2013
8.
Plaper PG et al. Double-blind, randomized, double-dummy clinical trial comparing the  
              efficacy of ketorolac trometamol and naproxen for acute low back pain. Drug design,    
              Development and Therapy. 2016 Jun 17;10:1987-93. doi: 10.2147/DDDT.S97756.    
              eCollection 2016.
9.          Olmedo MV, Galvez R, Vallecillo M. Double-blind parallel comparison of multiple doses    
              of ketorolac, ketoprofen and placebo administered orally to patients with postoperative   
              dental pain. Pain. 2001 Feb 1;90(1-2):135-41.
10.
Friedman BW, O'Mahony S, Mulvey L, Davitt M, Choi H, Xia S, et al. One-week and 3-month 
outcomes after an emergency department visit for undifferentiated musculoskeletal low 
back pain. Annals of emergency medicine. 2012;59(2):128-33 e3.
11.
Deyo RA, Battie M, Beurskens AJ, Bombardier C, Croft P, Koes B, et al. Outcome measures 
for low back pain research. A proposal for standardized use. Spine. 1998;23(18):2003-13.
IRB NUMBER: 2019-10026
IRB APPROVAL DATE: 04/17/2019

ketorolac vs other NSAIDS randomized trial Version 03312019
8
Appendix 1. Roland Morris low back pain disability questionnaire
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
Over the last 24 hours, I have stayed home most of the time because of my back pain:
Over the last 24 hours, I changed position frequently to try to get my back comfortable:
Over the last 24 hours, I walked more slowly than usual because of my back:
Over the last 24 hours, I have not been doing any jobs that I usually do around the house 
because of my back pain:
Over the last 24 hours, I used a handrail to get upstairs because of my back pain:
Over the last 24 hours, I lay down to rest more often because of my back pain:
Over the last 24 hours, I have had to hold on to something to get out of an easy chair 
because of my back pain
Over the last 24 hours, I have tried to get other people to do things for me because of my 
back pain:
Over the last 24 hours, I got dressed more slowly than usual because of my back pain:
Over the last 24 hours, I only stood up for short periods of time because of my back pain:
Over the last 24 hours, I tried not to bend or kneel down because of my back pain:    
Over the last 24 hours, I found it difficult to get out of a chair because of my back pain:    
Over the last 24 hours, my back was painful almost all of the time:    
Over the last 24 hours, I found it difficult to turn over in bed because of my back pain:    
Over the last 24 hours, my appetite was not very good because of my back pain:    
Over the last 24 hours, I have had trouble putting on my socks ( or stockings) because of 
the pain in my back or leg:
Over the last 24 hours,  I could only walk short distances because of my back pain:
Over the last 24 hours, I slept less well because of my back:    
Over the last 24 hours, I got dressed with the help of someone else because of my back 
pain:   
Over the last 24 hours, I sat down for most of the day because of my back:   
Over the last 24 hours, I avoided heavy jobs around the house because of my back pain:    
Over the last 24 hours, I was more irritable and bad tempered with people than usual 
because of my back pain,
Over the last 24 hours, I went upstairs more slowly than usual  because of my back pain
Over the last 24 hours, I stayed in bed most of the time because of my back pain:    
No0     Yes1
No0     Yes1
No0     Yes1
No0     Yes1
No0     Yes1
No0     Yes1
No0     Yes1
No0     Yes1
No0     Yes1
No0     Yes1
No0     Yes1
No0     Yes1
No0     Yes1
No0     Yes1
No0     Yes1
No0     Yes1
No0     Yes1
No0     Yes1
No0     Yes1
No0     Yes1
No0     Yes1
No0     Yes1
No0     Yes1
No0     Yes1
IRB NUMBER: 2019-10026
IRB APPROVAL DATE: 04/17/2019